Every life science product exists within an ecosystem comprised of key stakeholders. Understanding and addressing the needs of these stakeholders demands an integrated approach. To meet this requirement, Snowfish has developed solutions to help aid therapy interest and uptake by optimizing engagement with three main groups: patients, clinicians, and medical/advocacy organizations on a global basis.
Details

AI in life sciences is here to stay. Artificial Intelligence (AI) and machine learning are rapidly accelerating the drug discovery and development process in the life science industry. Initially conceived in the 1950s, artificial intelligence today, according to the NCBI, is a technology system involving various advanced tools and networks that can mimic human intelligence
Details

In the life science industry, product development has evolved into a costly endeavor. Translational tools seek to change this. Despite the promise of a novel molecule, it is an unfortunate fact of the life science industry that an overwhelming majority of discoveries will never result in new treatments. In fact, Valdes et al. 2018 finds
Details

Despite being discovered 65 years ago, messenger-RNA (mRNA), specifically mRNA vaccines, is making waves in the pharmaceutical industry. Pfizer/Biotech and Modernas’ COVID-19 vaccines credit their success to mRNA, causing other industry players to follow suit. Sanofi just announced it will invest $476 million dollars into the development of mRNA based vaccines. As with any new
Details

With billions of dollars on the line, a thorough analysis of the market landscape for your life science product is of utmost importance. Entering new markets is a high stakes hurdle for life science companies. Wouters et al. estimates that it costs an average of $1.3 billion to bring a new medicine to market.  Compounding
Details

The Pfizer COVID pill is the latest feat of strength from the New York-based pharmaceutical firm. To pair with its robust vaccine, Pfizer recently announced the development of an experimental antiviral drug that, for all intents and purposes, will break the pandemic. Unfortunately, in a pandemic, a vaccine on its own has never been enough.
Details

“Stakeholder Analysis and Engagement are critical to the launch and staying power of your product.” You have heard that wisdom before, but on top of seven to nine phone calls a day and hours spent in meetings, you may not have time to complete a truly thorough Stakeholder Analysis. Still, you are bombarded with calls
Details

In possibly the greatest product development race of this century, Pfizer, Moderna, and Johnson and Johnson (J&J) have emerged victorious. These firms beat out 6 other pharmaceutical companies, including titans AstraZeneca PLC and GlaxoSmithKline, in the race to develop a COVID-19 vaccine. A lot of lessons should be learned from this pandemic. For this post,
Details

Despite an average vaccination rate of 1.41 million doses per day in the U.S, the pandemic continues to take its toll on the population. In our last post, my colleague wrote of his relative who unfortunately contracted coronavirus. However, we are pleased to inform that she received a monoclonal antibodies treatment, and is currently recovering.
Details

This past week, a dear family member, an older adult, found that she has COVID-19. After her husband was diagnosed and hospitalized, she got tested and was shocked to find herself positive. She immediately called her primary care physician he did not send her immediately for any treatment such as a monoclonal antibody. In fact,
Details